Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå : ¾à¹° Á¾·ùº°, Åõ¿© °æ·Îº°, À¯Çüº°, ¼ºº°, À¯Åë ä³Îº°, Áö¿ªº°
Pulmonary Arterial Hypertension Drug Market, By Drug Class, By Route of Administration, By Type, By Gender, By Distribution Channel, By Geography
»óǰÄÚµå : 1671846
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2025³â 02¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,511,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 10,128,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,469,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2025³â 85¾ï 8,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö CAGR 5.9%·Î ¼ºÀåÇÏ¿© 2032³â¿¡´Â 128¾ï 1,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º¸°í¼­ ¹üÀ§ º¸°í¼­ »ó¼¼
±âÁØ ¿¬µµ 2024³â 2025³â ½ÃÀå ±Ô¸ð 85¾ï 8,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2020-2024³â ¿¹Ãø ±â°£ 2025-2032³â
¿¹Ãø ±â°£ : 2025-2032³â CAGR 5.90% 2032³â °¡Ä¡ ¿¹Ãø 128¾ï 1,000¸¸ ´Þ·¯
±×¸². Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2025³â
Pulmonary Arterial Hypertension Drug Market-IMG1

¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀåÀº Áö³­ ¸î ³â µ¿¾È ²ÙÁØÇÑ ¼ºÀå¼¼¸¦ º¸À̰í ÀÖ½À´Ï´Ù. Æóµ¿¸Æ °íÇ÷¾ÐÀº ½ÉÀå°ú Æó¸¦ ¿¬°áÇÏ´Â µ¿¸ÆÀÇ Ç÷¾ÐÀÌ ºñÁ¤»óÀûÀ¸·Î ³ôÀº °ÍÀÌ Æ¯Â¡ÀÎ ÁúȯÀÔ´Ï´Ù. °úµµÇÑ ¾Ð·ÂÀº »ê¼Ò¸¦ ¾ò±â À§ÇØ Æó¸¦ ÅëÇØ Ç÷¾×À» ³»º¸³»´Â ½ÉÀåÀÇ ±â´ÉÀ» ÀúÇϽÃŵ´Ï´Ù. Ä¡·á°¡ ´Ê¾îÁö¸é Áõ»óÀÌ ¾ÇÈ­µÇ¾î ½ÉºÎÀüÀ¸·Î À̾îÁú ¼ö ÀÖ½À´Ï´Ù. À§Çè¿äÀÎÀÇ Áõ°¡·Î ÀÎÇÑ Æóµ¿¸Æ °íÇ÷¾ÐÀÇ À¯º´·ü Áõ°¡, »õ·Ó°í È¿°úÀûÀÎ Ä¡·áÁ¦ÀÇ ½ÂÀÎ, Áø´ÜÀÇ °³¼± µîÀÇ ¿äÀÎÀÌ Àü ¼¼°èÀûÀ¸·Î ƯÁ¤ ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÁÖµµÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ³ôÀº Ä¡·á ºñ¿ë°ú Àå±âÀûÀÎ ¾à¹° »ç¿ë¿¡ µû¸¥ ºÎÀÛ¿ëÀº ¿©ÀüÈ÷ Å« ¹®Á¦Á¡À¸·Î ³²¾ÆÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀåÀº °í·ÉÈ­, À¯ÀüÀû ¼ÒÀÎ, ±âŸ Áúȯ µî À§Çè¿äÀÎÀÇ Áõ°¡·Î ÀÎÇÑ Æóµ¿¸Æ °íÇ÷¾Ð À¯º´·ü Áõ°¡ µîÀÇ ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ±¹¸³ ÀÇÇÐ µµ¼­°üÀÇ ÃßÁ¤¿¡ µû¸£¸é, 2024³â 11¿ù ºÏ¹Ì¿Í À¯·´¿¡¼­ 10¸¸ ¸í ÀÌ»óÀÌ Æóµ¿¸Æ °íÇ÷¾ÐÀ» ¾Î°í ÀÖ´Â °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ¶ÇÇÑ, ÇÁ·Î½ºÅ¸»çÀÌŬ¸° À¯»çü, ¿£µµ¼¼¸° ¼ö¿ëü ±æÇ×Á¦, Æ÷½ºÆ÷µð¿¡½ºÅͶó¾ÆÁ¦-5 ¾ïÁ¦Á¦ µî È¿´É°ú ÆíÀǼºÀ» Çâ»ó½ÃŰ´Â ½Å¾àÀÇ ½ÂÀεµ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ±×·¯³ª ºê·£µå ÀǾàǰÀÇ ³ôÀº °¡°ÝÀº ¿©ÀüÈ÷ ÁÖ¿ä ¾ïÁ¦¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù. Æóµ¿¸Æ °íÇ÷¾ÐÀ» Ä¡·áÇϱâ À§Çؼ­´Â Æò»ý ¾àÀ» º¹¿ëÇØ¾ß Çϸç, ¸Å³â ¼öõ ´Þ·¯ÀÇ ºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. ÀÌ ¶§¹®¿¡ ¾à¹°¿¡ ´ëÇÑ Á¢±ÙÀÌ Á¦ÇѵǾî ÀÖ½À´Ï´Ù. ±×·¯³ª Àú°¡ÀÇ Á¦³×¸¯ ÀǾàǰÀÇ ÃâÇöÀº ½ÃÀå Âü¿©Àڵ鿡°Ô »õ·Î¿î ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀåÀ» »ó¼¼È÷ ºÐ¼®ÇßÀ¸¸ç, 2024³âÀ» ±âÁØ ¿¬µµ·Î ÇÏ¿© ¿¹Ãø ±â°£(2025-2032³â)ÀÇ ½ÃÀå ±Ô¸ð¿Í ¿¬Æò±Õ ¼ºÀå·ü(CAGR)À» Á¶»çÇÏ¿© ÀüÇØµå¸³´Ï´Ù.

¶ÇÇÑ, ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀû ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í, ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¸¦ ¼³¸íÇÕ´Ï´Ù.

¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÇ °æÀï Àü·« µî¿¡ ´ëÇÑ Áß¿äÇÑ ÀλçÀÌÆ®¸¦ Á¦°øÇÕ´Ï´Ù.

¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» ±â¾÷ °³¿ä, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä Æ¯Â¡, ÁÖ¿ä ¼º°ú, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î Á¤¸®ÇÏ¿© ¼ö·ÏÇÏ¿´½À´Ï´Ù.

ÁÖ¿ä ±â¾÷À¸·Î´Â United Therapeutics Corporation, Actelion Pharmaceuticals(a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck &Co, Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., Lupin Pharmaceuticals, Inc. µîÀÌ ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯ÇüÈ­, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü·«¿¡ ´ëÇÑ Á¤º¸¿¡ ÀÔ°¢ÇÑ ÀÇ»ç°áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå º¸°í¼­´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô ÁøÀÔÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.

ÀÌÇØ°ü°èÀÚµéÀº ¼¼°è Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ½±°Ô ³»¸± ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»ç ¸ñÀû°ú °¡Á¤

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, ¾à¹° Á¾·ùº°, 2020-2032³â

Á¦5Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2020-2032³â

Á¦6Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, À¯Çüº°, 2020-2032³â

Á¦7Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, ¼ºº°, 2020-2032³â

Á¦8Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, À¯Åë ä³Îº°, 2020-2032³â

Á¦9Àå ¼¼°èÀÇ Æóµ¿¸Æ °íÇ÷¾Ð Ä¡·áÁ¦ ½ÃÀå, Áö¿ªº°, 2020-2032³â

Á¦10Àå °æÀï ±¸µµ

Á¦11Àå ¾Ö³Î¸®½ºÆ®ÀÇ Ãßõ»çÇ×

Á¦12Àå Âü°í¹®Çå°ú Á¶»ç ¹æ¹ý

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at US$ 8.58 Bn in 2025 and is expected to reach US$ 12.81 Bn by 2032, growing at a compound annual growth rate (CAGR) of 5.9% from 2025 to 2032.

Report Coverage Report Details
Base Year: 2024 Market Size in 2025: US$ 8.58 Bn
Historical Data for: 2020 To 2024 Forecast Period: 2025 To 2032
Forecast Period 2025 to 2032 CAGR: 5.90% 2032 Value Projection: US$ 12.81 Bn
Figure. Pulmonary Arterial Hypertension Drug Market Share (%), By Region 2025
Pulmonary Arterial Hypertension Drug Market - IMG1

The global pulmonary arterial hypertension drug market has been witnessing steady growth over the past few years. Pulmonary arterial hypertension is a condition characterized by abnormally high blood pressure in the arteries connecting the heart and lungs. The excessive pressure makes the heart work harder to pump blood through the lungs to obtain oxygen. If not treated on time, the condition can lead to worsening symptoms and even heart failure. Factors such as the growing prevalence of pulmonary arterial hypertension due to increasing risk factors, approval of new and effective treatment drugs, and improved diagnosis are driving the demand for specific drugs globally. However, high treatment costs and side effects associated with long term use of drugs continue to remain major challenges.

Market Dynamics:

The global pulmonary arterial hypertension drug market is driven by factors such as the increasing prevalence of pulmonary arterial hypertension due to growing risk factors like older age, genetic predisposition, and other medical conditions. In November 2024, according to National Library of Medicine estimates, more than 100,000 people in North America and Europe suffer from pulmonary arterial hypertension. Furthermore, approval of new drugs such as prostacyclin analogs, Endothelin receptor antagonists, Phosphodiesterase-5 inhibitors, and others which offer improved efficacy and convenience is also fueling market growth. However, the high cost of branded drugs remains a key restraint. Treatment of pulmonary arterial hypertension requires life-long medication which costs thousands of dollars every year. This limits accessibility to medication. Nevertheless, emergence of low-cost generic drugs is expected to create new opportunities for market players.

Key Features of the Study:

This report provides in-depth analysis of the global pulmonary arterial hypertension drug market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year

It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market

This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players

It profiles key players in the global pulmonary arterial hypertension drug market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies

Key companies covered as a part of this study include United Therapeutics Corporation, Actelion Pharmaceuticals (a Janssen Pharmaceutical Company), Bayer AG, Gilead Sciences, Inc., Merck & Co., Inc., GlaxoSmithKline plc, Pfizer Inc., Novartis International AG, Teva Pharmaceutical Industries Ltd., Amgen Inc., Bristol-Myers Squibb Company, Arena Pharmaceuticals, Sun Pharmaceutical Industries Ltd., Sandoz Inc., and Lupin Pharmaceuticals, Inc.

Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics

The global pulmonary arterial hypertension drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts

Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pulmonary arterial hypertension drug market

Market Segmentation

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Pulmonary Arterial Hypertension Drug Market, By Drug Class, 2020-2032, (USD Bn)

5. Global Pulmonary Arterial Hypertension Drug Market, By Route of Administration, 2020-2032, (USD Bn)

6. Global Pulmonary Arterial Hypertension Drug Market, By Type, 2020-2032, (USD Bn)

7. Global Pulmonary Arterial Hypertension Drug Market, By Gender, 2020-2032, (USD Bn)

8. Global Pulmonary Arterial Hypertension Drug Market, By Distribution Channel, 2020-2032, (USD Bn)

9. Global Pulmonary Arterial Hypertension Drug Market, By Region, 2020 - 2032, Value (USD Bn)

10. Competitive Landscape

11. Analyst Recommendations

12. References and Research Methodology

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â